Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Bulletin Du Cancer
|
July 24, 2002
[Cl958]
Amélie Lansiaux, Armelle Caty, Nathalie Deligny, et al.
Acta Oncologica (Stockholm, Sweden)
|
September 23, 2011
Prostate cancer related haemophagocytic syndrome: successful treatment with chemotherapy
Lydie Declerck, Claude Adenis, Eric Amela, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
February 15, 2008
[Gastric or duodenal metastases from clear cell renal cell carcinoma. Report of two cases and review of the literature]
Jérémie Haffner, Jean-François Morel, Vincent Maunoury, et al.
Bulletin Du Cancer
|
December 11, 2012
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
Marie Vanhuyse, Nicolas Penel, Armelle Caty, et al.
Gastroenterologie Clinique Et Biologique
|
January 2, 2008
[Endoscopic treatment of hemorrhagic gastric metastases in renal cell carcinoma]
Vincent Maunoury, Jean-François Morel, Agnès Wacrenier, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
February 3, 2009
Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis
Benjamin Besse, Dominique Grunenwald, Aude Fléchon, et al.
European Urology
|
December 2, 2008
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial
Nicholas D James, Armelle Caty, Michael Borre, et al.
Cancer
|
October 13, 2007
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial
Sylvie Negrier, David Perol, Alain Ravaud, et al.
Bulletin Du Cancer
|
October 9, 2014
[Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?]
Antoine Thiery-Vuillemin, Guillaume Mouillet, Damien Pouessel, et al.
BJU International
|
September 16, 2010
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial
Nicholas D James, Armelle Caty, Heather Payne, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Bulletin Du Cancer
|
July 24, 2002
[Cl958]
Amélie Lansiaux, Armelle Caty, Nathalie Deligny, et al.
Acta Oncologica (Stockholm, Sweden)
|
September 23, 2011
Prostate cancer related haemophagocytic syndrome: successful treatment with chemotherapy
Lydie Declerck, Claude Adenis, Eric Amela, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
February 15, 2008
[Gastric or duodenal metastases from clear cell renal cell carcinoma. Report of two cases and review of the literature]
Jérémie Haffner, Jean-François Morel, Vincent Maunoury, et al.
Bulletin Du Cancer
|
December 11, 2012
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
Marie Vanhuyse, Nicolas Penel, Armelle Caty, et al.
Gastroenterologie Clinique Et Biologique
|
January 2, 2008
[Endoscopic treatment of hemorrhagic gastric metastases in renal cell carcinoma]
Vincent Maunoury, Jean-François Morel, Agnès Wacrenier, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
February 3, 2009
Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis
Benjamin Besse, Dominique Grunenwald, Aude Fléchon, et al.
European Urology
|
December 2, 2008
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial
Nicholas D James, Armelle Caty, Michael Borre, et al.
Cancer
|
October 13, 2007
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial
Sylvie Negrier, David Perol, Alain Ravaud, et al.
Bulletin Du Cancer
|
October 9, 2014
[Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?]
Antoine Thiery-Vuillemin, Guillaume Mouillet, Damien Pouessel, et al.
BJU International
|
September 16, 2010
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial
Nicholas D James, Armelle Caty, Heather Payne, et al.
Page
of 2